grant
Clinical and Molecular based prognostic factors for Venous Thromboembolism (VTE) in Children with Sickle Cell Disease
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 15 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldAT III-protease complexAccountingAchievementAchievement AttainmentAddressAdhesion MoleculeAdultAdult HumanAffectAfricanAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAnticoagulant AgentsAnticoagulant DrugsAnticoagulantsAreaArea Under CurveAssayAttentionAwardB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BioassayBiologicalBiological AssayBiological MarkersBiological Specimen BanksBiological Substance BanksBlackBlack raceBlood Coagulation Factor IIIBlood DiseasesBlood PlasmaCD142 AntigensCD62P AntigensCase-Base StudiesCase-Comparison StudiesCase-Compeer StudiesCase-Referent StudiesCase-Referrent StudiesCase/Control StudiesCathetersCell AdhesionCell Adhesion Molecule GeneCell Adhesion MoleculesCellular AdhesionCessation of lifeChildChild YouthChildhoodChildren (0-21)ChronicClinicalClinical DataClinical InvestigatorClottingCoagulationCoagulation Factor IIICoagulation ProcessCoagulinCohort StudiesComplicationComputerized Medical RecordConcurrent StudiesCountryCoupledCytolysisDataData BasesDatabasesDeathDevelopmentDevelopment PlansDiseaseDisorderDrugsEducation and TrainingElectronic Medical RecordEndotheliumEventFactor IIIFrequenciesFutureGMP-140General Prognostic FactorGenotypeGlomerular Procoagulant ActivityGoalsHPGFHb SS diseaseHbSS diseaseHematologic DiseasesHematological DiseaseHematological DisorderHemoglobin S DiseaseHemoglobin SSHemoglobin sickle cell diseaseHemoglobin sickle cell disorderHepatocyte-Stimulating FactorHereditaryHistoryHospital AdmissionHospitalizationHybridoma Growth FactorHypercoagulabilityIFN-beta 2IFNB2IL-6IL6 ProteinIncidenceIndividualInflammationInflammatoryInheritedInterleukin-6InterleukinsIntervention StudiesIntervention TrialInterventional trialInvestigationInvestigatorsKnowledgeLECAM-3LifeLogistic RegressionsLow incomeLysisMGI-2Mass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMedicationMentorsMethodsMinorityModelingMolecularMyeloid Differentiation-Inducing ProteinNational Institutes of HealthObservation researchObservation studyObservational StudyObservational researchOrganOutcomeP-SelectinPRBC TransfusionPacked Red Blood Cell TransfusionPathogenesisPathway interactionsPatientsPediatric HematologyPersonsPharmaceutical PreparationsPlasmaPlasma SerumPlasmacytoma Growth FactorPlatelet alpha-Granule Membrane ProteinPopulationPrevention trialPrimary PreventionPrognostic FactorPrognostic/Survival FactorProteomicsProthrombinaseRecording of previous eventsRecurrenceRecurrentRegression AnalysesRegression AnalysisRegression DiagnosticsResearchResearch PersonnelResearch PriorityResearch SpecimenResearchersReticuloendothelial System, Serum, PlasmaRetrospective cohortRetrospective cohort studyRiskRisk FactorsSecondary PreventionSecondary toSickle Cell AnemiaSpecimenSplenectomyStatistical RegressionSystemThrombin-Antithrombin ComplexThrombophiliaThromboplastinTissue FactorTissue Factor ProcoagulantTissue ThromboplastinTrainingTraining and EducationUnited StatesUnited States National Institutes of HealthUrothromboplastinValidationVenousWorkacute chest syndromeadulthoodantithrombin III-protease complexbio-markersbiobankbiologicbiologic markerbiological specimen repositorybiomarkerbiomarker developmentbiomarker discoverybiomarker validationbiorepositorybiosample repositorybiospecimen bankbiospecimen repositoryblood disorderblood thinnercareercareer developmentcase-controlled studiescell adhesion proteinchild patientsclinical prognosticclinical riskdata basedata collected in real worlddesigndesigningdevelopmentaldrug/agentearly onsethigh riskhistoriesimproved outcomeinterestinterferon beta 2intervention researchinterventional researchinterventional studyinterventions researchkidsmarker validationnew markernovelnovel biomarkernovel markerpathwaypediatricpediatric patientsprognosis modelprognostic modelprognostic profileprognostic signatureprospectivereal world datarisk stratificationsickle cell diseasesickle cell disordersickle diseasesicklemiaspecimen bankspecimen repositorystratify riskthrombin-antithrombin III complexthrombopoiesis inhibitortranslational investigatortranslational researchertranslational scientistvalidationsvascular endothelial dysfunctionvenous thromboembolismyoungster
Description preview
PROJECT SUMMARY
Sickle cell disease (SCD) is a multi-system, life-threatening, inherited blood disorder that disproportionally affects
low-income vulnerable minorities in the United States. Of the approximately 100,000 individuals living with this
condition in the country, people of African descend account for 90% of patients. A hallmark of the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click